Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.2.1.7 (BAL)
 1,977 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum and BAL CEA levels were determined in stage I (WHO scale) lung cancer patients. The immuno-enzyme assay for the quantitative determination of CEA according to enzyme-linked immunosorbent assay (ELISA) principle was used. Eight smokers without symptoms of respiratory disease served as a control group. The CEA levels were also determined in 48 patients with chronic bronchitis to evaluate the influence the role of the inflammatory processes of the respiratory tract in producing CAE. All determined serum, and BAL fluid CEA levels were related to total protein and albumin for comparison of both media. It was shown that the BAL fluid CEA levels in lung cancer patients exceeded 10-fold the control levels, and twice fold the levels found in chronic bronchitis. It must be emphasized that serum levels were within normal limits in all analysed groups. The concentration of CEA expressed as ratio to total protein and albumin supported a diagnostic usefulness of CEA in BAL and indicated a slight modification of it by inflammatory process.
 ...
PMID:[Concentration of carcinoembryonic antigen in the serum and bronchoalveolar lavage fluid in patients with lung cancer]. 263 45

Numerous studies have been performed to determine diagnostic or prognostic utility of tumor markers in patients with lung cancer. The aim of the study was to evaluate the diagnostic usefulness of the tumor markers CA 125, CEA and CYFRA 21-1 in bronchoalveolar lavage fluid (BALF) in patients with non-small cell lung cancer (NSCLC). BAL was performed in 13 patients with NSCLC during diagnostic bronchofibroscopy. The control group consisted of 12 patients with sarcoidosis and 13 healthy volunteers. Tumor markers were determined in BALF supernatants using electrochemiluminescence technique (Elecsys 1010, Roche). To determine optimal cut-off values of tumor markers in BALF ROC curve was used. CEA and CA 125 concentration in BALF were significantly higher in NSCLC patients than in healthy volunteers and patients with sarcoidosis. CYFRA 21-1 in BALF was higher in NSCLC patients than in healthy volunteers, but no significant difference was found between NSCLC and sarcoidosis patients. The cut-off values of BALF concentration of CA 125, CEA and CYFRA 21-1 were 95 IU/mL, 3 ng/ml and 3 ng/ml, respectively. The sensitivity and specificity of CEA and CA 125 in BALF were 100%, 84% and 92%, 80%, respectively. In conclusion, we suggest that among the chosen markers, determination of CEA in BALF is the most useful in diagnosis of NSCLC. It may be a complementary method in diagnosing of patients in whom tumor cannot be visualized by bronchofibroscopy. These results need confirmation in larger groups of patients.
 ...
PMID:[Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer]. 1550 87